Overview of Caverta 100 mg Research Applications
Caverta 100 mg Ranbaxy is a sildenafil citrate formulation developed by Ranbaxy Laboratories for investigating phosphodiesterase-5 (PDE5) enzyme inhibition mechanisms. Each tablet contains 100 mg of sildenafil citrate, enabling researchers to examine selective PDE5 inhibition pathways and associated vascular smooth muscle responses in controlled laboratory environments. This research-grade compound serves as a valuable tool for studying cyclic guanosine monophosphate (cGMP) signalling cascades and nitric oxide-dependent vascular mechanisms. Investigators at Stroid UK Shop can explore this compound alongside other research chemicals for comprehensive vascular biology studies.
Research Applications and Mechanisms
Sildenafil citrate operates through selective inhibition of phosphodiesterase type 5, preventing the breakdown of cyclic guanosine monophosphate within vascular smooth muscle cells. This mechanism enables researchers to investigate nitric oxide-dependent signalling pathways and their effects on smooth muscle relaxation in various tissue models. Laboratory studies utilising Caverta 100 mg can examine the compound’s effects on pulmonary arterial pressure, cardiac output parameters, and peripheral vascular resistance measurements. The research potential extends to investigating molecular interactions with other PDE enzyme subtypes and comparative efficacy studies with alternative PDE5 inhibitors. Scientists often incorporate this compound into broader research protocols examining cardiovascular pharmacology, particularly when studying sildenafil citrate formulations in controlled laboratory settings.
Technical Specifications
| Active Compound | Sildenafil Citrate |
|---|---|
| Concentration | 100 mg per tablet |
| Manufacturer | Ranbaxy Laboratories |
| Form | Oral tablet |
| CAS Number | 171599-83-0 (sildenafil citrate) |
| Molecular Formula | C₂₈H₃₈N₆O₁₁S |
| Storage Requirements | Room temperature, dry environment |
| Research Applications | PDE5 inhibition studies, vascular research |
Research protocols should account for the compound’s stability characteristics and optimal storage conditions to maintain molecular integrity throughout experimental procedures. Investigators studying selective androgen receptor modulators and peptide compounds may find comparative studies with PDE5 inhibitors valuable for understanding different molecular mechanisms affecting vascular function and smooth muscle regulation in laboratory models.
Laboratory Use and Safety
This product is manufactured exclusively for in-vitro research applications and laboratory investigation purposes. Caverta 100 mg Ranbaxy should be handled using appropriate laboratory safety protocols, including proper ventilation, protective equipment, and controlled access procedures. Research institutions must ensure adequate training for personnel handling phosphodiesterase inhibitors and maintain detailed documentation of experimental protocols and outcomes. This product is not intended for human consumption, veterinary use, or any application outside controlled laboratory environments. All research applications must comply with institutional guidelines and relevant regulatory frameworks governing laboratory chemical use.
